比较顺铂联合吉西他滨与顺铂联合培美曲塞一线治疗晚期非小细胞肺癌的III期研究
这项非劣效性III期随机研究纳入1725例未接受化疗的IIIB或IV期非小细胞肺癌患者,比较顺铂联合培美曲塞与顺铂联合吉西他滨的总生存。顺铂联合培美曲塞的总生存非劣效于顺铂联合吉西他滨(中位生存10.3个月对10.3个月,HR=0.94,95%CI 0.84至1.05),且在腺癌和大细胞癌组织学患者中总生存更优,而在鳞癌患者中顺铂联合吉西他滨更优。
要点
- 顺铂联合培美曲塞总生存非劣效于顺铂联合吉西他滨(HR=0.94,95%CI 0.84至1.05)。
- 腺癌患者中顺铂联合培美曲塞中位生存12.6个月对顺铂联合吉西他滨10.9个月。
- 鳞癌患者中顺铂联合吉西他滨中位生存10.8个月对顺铂联合培美曲塞9.4个月。
核心结论
- 在晚期非小细胞肺癌中,顺铂联合培美曲塞与顺铂联合吉西他滨疗效相似,但耐受性更好且给药更方便。
- 这是首个在非小细胞肺癌中显示基于组织学类型生存差异的前瞻性III期研究。
研究设计与样本
- 非劣效性III期随机研究,采用固定界值法(风险比[HR]小于1.176)比较两组总生存。
- 纳入1725例未接受化疗的IIIB或IV期非小细胞肺癌患者,美国东部肿瘤协作组体能状态评分为0至1。
- 顺铂联合吉西他滨组863例:顺铂75 mg/m2第1天,吉西他滨1,250 mg/m2第1天和第8天。
- 顺铂联合培美曲塞组862例:顺铂75 mg/m2和培美曲塞500 mg/m2第1天。
- 每3周一次,最多6个周期。
主要发现
- 顺铂联合培美曲塞组中位生存10.3个月,顺铂联合吉西他滨组中位生存10.3个月,HR=0.94,95%CI 0.84至1.05。
- 腺癌患者(n=847)中位生存:顺铂联合培美曲塞组12.6个月对顺铂联合吉西他滨组10.9个月。
- 大细胞癌患者(n=153)中位生存:顺铂联合培美曲塞组10.4个月对顺铂联合吉西他滨组6.7个月。
- 鳞癌患者(n=473)中位生存:顺铂联合吉西他滨组10.8个月对顺铂联合培美曲塞组9.4个月。
- 顺铂联合培美曲塞组3或4级中性粒细胞减少、贫血和血小板减少(P≤.001)、发热性中性粒细胞减少(P=.002)和脱发(P<.001)发生率显著更低,而3或4级恶心(P=.004)更常见。
关键数值与推荐
- 非劣效界值为HR小于1.176。
- 总体人群中位生存10.3个月对10.3个月,HR=0.94,95%CI 0.84至1.05。
- 腺癌患者中位生存12.6个月对10.9个月。
- 大细胞癌患者中位生存10.4个月对6.7个月。
- 鳞癌患者中位生存10.8个月对9.4个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS: This noninferiority, phase III, randomized study compared the overall survival between treatment arms using a fixed margin method (hazard ratio [HR] < 1.176) in 1,725 chemotherapy-naive patients with stage IIIB or IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 1. Patients received cisplatin 75 mg/m2 on day 1 and gemcitabine 1,250 mg/m2 on days 1 and 8 (n = 863) or cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on day 1 (n = 862) every 3 weeks for up to six cycles. RESULTS: Overall survival for cisplatin/pemetrexed was noninferior to cisplatin/gemcitabine (median survival, 10.3 v 10.3 months, respectively; HR = 0.94; 95% CI, 0.84 to 1.05). Overall survival was statistically superior for cisplatin/pemetrexed versus cisplatin/gemcitabine in patients with adenocarcinoma (n = 847; 12.6 v 10.9 months, respectively) and large-cell carcinoma histology (n = 153; 10.4 v 6.7 months, respectively). In contrast, in patients with squamous cell histology, there was a significant improvement in survival with cisplatin/gemcitabine versus cisplatin/pemetrexed (n = 473; 10.8 v 9.4 months, respectively). For cisplatin/pemetrexed, rates of grade 3 or 4 neutropenia, anemia, and thrombocytopenia (P ≤ .001); febrile neutropenia (P = .002); and alopecia (P < .001) were significantly lower, whereas grade 3 or 4 nausea (P = .004) was more common. CONCLUSION: In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. This is the first prospective phase III study in NSCLC to show survival differences based on histologic type.
引用
- Scagliotti GV, Parikh P, von Pawel J, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 37146426. doi:10.1200/JCO.22.02544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。